Tevogen Bio Holdings Inc. (TVGN)
NASDAQ: TVGN · IEX Real-Time Price · USD
1.850
-0.270 (-12.74%)
At close: Apr 19, 2024, 4:00 PM
1.890
+0.040 (2.16%)
After-hours: Apr 19, 2024, 7:48 PM EDT
Company Description
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.
Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID.
The company is based in Warren, New Jersey.
Tevogen Bio Holdings Inc.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. |
Contact Details
Address: 15 Independence Boulevard, Suite 410 Warren, New Jersey 07059 United States | |
| Phone | 646-807-8832 |
| Website | tevogen.com |
Stock Details
| Ticker Symbol | TVGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860871 |
| ISIN Number | US88165K1016 |
| Employer ID | 98-1597194 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, Chief Executive Officer and Chairman |
| Kirti Desai | Chief Financial Officer and Director |
| Stephen Chen M.B.A. | Chief Technical Officer |
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer, Global Research & Development Lead and Chairman of Corporate Board |
| Mittul Mehta | Chief Information Officer and Head of Tevogen.ai |
| Tapan V. Shah | Head of Investor Relations and Corporate Development |
| Jeffrey Feike M.P.H. | Chief Patient Officer, Member of Innovation and Public Health Advisory Council & Director |
| Sadiq Khan | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | 8-K/A | [Amend] Current report |
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 21, 2024 | 8-K | Current Report |
| Feb 20, 2024 | 8-K/A | [Amend] Current report |
| Feb 15, 2024 | CERT | Certification by an exchange approving securities for listing |